213 results about "Hypertension medications" patented technology

The present invention relates to compositions comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

Methods and compositions for improving the delivery and/or efficacy of a therapy (e.g., a cancer therapy) are disclosed. In one embodiment, methods and compositions for treating or preventing a cancer (e.g., a solid tumor such as a desmoplastic tumor) by administering to a subject an anti-hypertensive agent, as a single agent or in combination with a microenvironment modulator and/or a therapy, e.g., a cancer therapy (for example, a therapeutic agent or therapy, including immunotherapy (e.g., antibodies, vaccine, cell-based), nanotherapeutics, radiation therapy, photodynamic therapy, low molecular weight chemotherapeutics, molecularly targeted therapeutics and/or oxygen radical) are disclosed.

The present invention relates to a composition for the treatment and/or prevention of hypertension, said composition comprising an synergistic anti-hypertensive combination of a therapeutically effective amount of at least one angiotensin II inhibitor, and a therapeutically effective amount of at least one nitric oxide donor; said composition optionally further comprising a pharmaceutically acceptable carrier, diluent and/or adjuvant.

A Phyto-nutraceutical composition for the prevention and treatment of hypertensive disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect.

Linear constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues and at least one amino acid surrogate of formula I:

where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group covalently bound to a reactive group of at least one of the amino acid residues or surrogates, pharmaceutical compositions including such linear constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.

The invention relates to the technical field of medicine, in particular to a new benzoxanthone type compound and an application thereof in pharmacy. Benzoxanthone type derivatives are one type of topoisomerase I inhibitors in new structure, which are found in recent years, and have obvious cell proliferation activity. The invention provides the new benzoxanthone type compound and pharmaceutical salts thereof, and the structure of the compound is as shown in the general formula (I). The invention further provides the application of the benzoxanthone type compound and the pharmaceutical salts thereof in the preparation of the topoisomerase inhibitors, anti-tumor medicaments, antifungal medicaments, antiviral medicaments, anti-hypertensive medicaments or anti-thrombotic medicaments.

The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption.

This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan, and Camptosar®, an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti-hypertensive agent. This invention also relates to pharmaceutical compositions useful in the treatment of hyperproliferative diseases in mammals, containing such combinations. The present invention also relates to kits having a first compartment with a compound of formula 1 and a second compartment containing a taxane derivative, a platinum coordination complex, a nucleoside analog, an anthracycline, a topoisomerase inhibitor, or an aromatase inhibitor and a third compartment containing an anti-hypertensive agent.

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

The invention belongs to the technical field of pharmaceutical chemistry and particularly discloses a benzimidazole derivative and a preparation method and medical application thereof. The benzimidazole derivative comprises a ligustrazine and an NO donor derivative and rapidly releases the ligustrazine or NO in vivo, accordingly the benzimidazole derivative and azilsartan produce effective synergistic effect, the anti-hypertensive treating effect is improved, the untoward effect is reduced, and the benzimidazole derivative has fairly ideal production effect on the liver and kidney of a patient and fills the blank in the prior art.

The invention concerns the use of a combination of an anti-angiogenic agent and an anti-hypertensive agent for use in the manufacture of a medicament for the treatment of a disease state associated with angiogenesis in a warm-blooded mammal, such as a human being. The invention also relates to pharmaceutical compositions comprising an anti-angiogenic agent and an anti-hypertensive agent, to kits thereof and to a method of treatment of a disease state associated with angiogenesis which comprises the administration of an effective amount of a combination of an anti-angiogenic agent and an anti-hypertensive agent to a warm-blooded animal, such as a human being.

The invention relates to the production of ovoproducts containing bioactive peptides from the egg white subjected to enzymatic treatment. Said peptides have an inhibiting activity of the angiotensin converting enzyme (ACE inhibiting activity) in vitro and/or anti-hypertensive activity in rats and/or antioxidant activity. Said ovoproducts, complete hydrolizates, the fractions thereof with low molecular weight or their constituent peptides could be used as therapeutic substances with ACE inhibiting activity and/or anti-hypertensive activity and/or anti-oxidant activity, either as functional food products, food additives or ingredients or pharmaceutical products for the treatment and/or prevention of hypertension in all its forms in humans or animals and for the treatment and/or prevention of any disorder associated with hypertension in humans or animals.

A complex formulation for oral administration comprising a sustained release formulation of an HMG-CoA reductase inhibitor and a film layer for rapid release of an anti-hypertensive agent, the film layer being coated on the sustained release formulation, can achieve improved therapeutic effects of the anti-hypertensive agent by promptly releasing it, while maintaining a constant drug level of the HMG-CoA reductase inhibitor in blood through a slow release. Accordingly, the complex formulation is useful for preventing and treating diseases such as hyperlipidemia, atherosclerosis, hypertension and cardiovascular disease.

The invention relates to a method for separating and purifying corn anti-hypertensive peptides, which belongs to a method for separating corn peptides from corn protein powder. The method for separating and purifying the corn anti-hypertensive peptides comprises the following steps of: hydrolyzing the corn protein powder the corn yellow pigment of which is removed by using alkali protease, filtering by adopting a plate frame filter to remove impurities, then filtering by a film, afterwards determining the molecular weight of a target product by the analysis of high-performance liquid chromatography, selecting a hydrolysate with the activity of lowering the blood pressure, and separating and purifying the hydrolysate with the activity of lowering the blood pressure by adopting a chromatographic separation system of a simulated moving bed so as to obtain the corn anti-hypertensive peptides. The separation and the purification are carried out by adopting an isocratic elution mode, wherein the feeding flow rate is 5 to 100ml/min; the flow rate of a mobile phase is 6.5 to 130ml/min, and the concentration of the mobile phase is 40 percent of ethanol; the flow rate of an outlet of a product is 4.5 to 90ml/min; and the flow rate of a circulating pump is 10 to 200ml/min, and the switching time is 6 to 120min. On the basis of achieving an industrialized level, the invention can separate the corn anti-hypertensive peptides with relatively higher purity.

A preparation containing vitamin D₃ (cholecalciferol), preferably an edible oil, in an amount of 200 IU to 20,000 IU, preferably 1000 IU to 5000 IU, and most preferably about 1500 IU to 3500 IU, with about 2000 IU particularly preferred. Such a preparation is useful in providing adequate nutrition, in the prevention and/or treatment of Seasonal Affective Disorder (SAD), fall prevention, multiple sclerosis, chemoprevention of cancer, accelerated fracture healing, and metabolic syndrome. It acts as an anti-depressant, an anti-hypertensive for renovascular hypertension and high-renin hypertension; and is useful in hyperlipidemia treatment, as well as in the treatment of hypovitaminosis D in the renal failure population. The most important application to the present inventors is in treatment, prevention and also reversal of hypertension in renovascular and high-renin hypertension. The effective amount of vitamin D, based on blood serum content, is equal to or greater than 20 ng/mL, preferably equal to or greater than 40 ng/mL, and most preferably equal to or greater than 50 ng/mL, with no specific upper range, but preferably equal to or less than 200 ng/mL, and more preferably equal to or less than 100 ng/mL.

The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g., edema, congestive heart failure) and/or in need of synergistic anti-inflammatory, anti-hypertensive, and anti-diabetic effect.

Compounds of the formulaare disclosed, wherein R1, represents secondary alkyl; aralkyl; cycloalkyl; heteroaryl substituted alkyl; norbornyl; and substituted secondary alkyl, aralkyl, cycloalkyl, heteroaryl substituted alkyl, norbornyl; and para-substituted phenyl groups; and R2 and R3 are hydrogen or pharmacologically acceptable acyl groups. The compounds of the invention are useful as cardiovascular vasodilator or anti-hypertensive agents. The therapeutically useful compounds of the invention as well as similar 5-N and N-6 substituted adenosine 5-uronamides are prepared, in accordance with a novel process, from isopropylidene (or otherwise suitably blocked) inosine-5'-uronic acid. Isopropylideneinosine-5'-uronic acid is reacted with a suitable inorganic acid halide, such as thionyl chloride, to yield 6-halogeno-9-[2',3'-O-isopropylidene-beta-D-ribofuranosyl-5-uronic acid halide]-9H-purine. This intermediate is reacted with an amine of the general formula R4R5NH to give a 6-halogeno substituted, substituted uronic acid amide of the formulawherein X is halogen. Reaction of the latter intermediate with an amine of the formula R1-NH2, and removal of the isopropylidene (or other) blocking groups yields the compounds of the invention.

The invention relates to a preparation method for a (S)-1,4-dihydropyridine calcium ion antagonist as shown in a formula (I); the (S)-1,4-dihydropyridine calcium ion antagonist is an anti-hypertension medicine. The preparation method comprises a step of condensing substituted benzylidene acetoacetate and beta-amino crotonate, wherein substituted benzylidene acetoacetate is catalyzed by chiral phosphoric acid as shown in a formula (IV) or a formula (V). The preparation method is mild in reaction condition, high in yield and optical purity, and suitable for industrialized production.

The invention discloses a method for producing bioactive peptide with a high blood pressure resistant function from casein, which comprises the steps of enzymolysis reaction and the desalting of zymolyte, wherein, zymolyte in the enzymolysis reaction is casein aqueous solution; prolease Alcalase is selected as enzyme; the consumption of the enzyme is 0.072 AU/g bioactive peptide; the temperature of the whole reaction process is controlled to be 55 DEG C to 60 DEG C; the pH value is between 8.4 to 8.6; the enzymolysis time is 5 to 6 hours. The invention also discloses the casein bioactive peptide prepared through the method. The bioactive peptide has good high blood pressure resistant function, and can be used to prepare high blood pressure resistant drinks, food or medicine.